Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer-Reference-Cited by-同舟云学术

Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer

Published:2017-04 Issue: Volume:106 Page:1-7
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Bagley Stephen J.,Kothari Shawn,Aggarwal Charu,Bauml Joshua M.,Alley Evan W.,Evans Tracey L.,Kosteva John A.,Ciunci Christine A.,Gabriel Peter E.,Thompson Jeffrey C.,Stonehouse-Lee Susan,Sherry Victoria E.,Gilbert Elizabeth,Eaby-Sandy Beth,Mutale Faith,DiLullo Gloria,Cohen Roger B.,Vachani Anil,Langer Corey J.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference35 articles.

1. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N. Engl. J. Med.,2015

2. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N. Engl. J. Med.,2015

3. Pembrolizumab for the treatment of non-small-cell lung cancer;Garon;N. Engl. J. Med.,2015

4. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;Lancet,2016

5. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer;Guthrie;Crit. Rev. Oncol. Hematol.,2013

Cited by 402 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Strategies for engineering oncolytic viruses to enhance cancer immunotherapy;Frontiers in Pharmacology;2024-09-06

2. Characterization of pre- and on-treatment soluble immune mediators and the tumor microenvironment in NSCLC patients receiving PD-1/L1 inhibitor monotherapy;Cancer Immunology, Immunotherapy;2024-09-05

3. Molecular Characteristics and Pretreatment Neutrophil-to-Lymphocyte Ratio as Predictors of Durable Clinical Benefit from Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer;CLIN LUNG CANCER;2024

4. Molecular Characteristics and Pretreatment Neutrophil-to-Lymphocyte Ratio as Predictors of Durable Clinical Benefit from Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer;Clinical Lung Cancer;2024-09

5. Unlocking the potential: the neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR) as biomarkers informing immunotherapy outcomes in lung cancer patients — single oncology center experience and literature review;Oncology in Clinical Practice;2024-08-21